Endometrial02, researchers want to see whether Enhertu can replace current standard-of-care chemotherapy for patients with HER2-expressing tumors.

NEW YORK – BioMarin has stopped developing the investigational BMN 349 for treating alpha-1 antitrypsin deficiency (AATD)-associated liver disease, the company announced in a regulatory filing this ...

Jacobio will get $100 million upfront in the deal and be entitled to an additional $1.92 billion upon meeting certain milestones related to JAB-23E73.

RheumaGen will use the funds to advance its therapeutic development program in celiac disease through preclinical proof of concept.

This year, there was a surge of new lung cancer treatments, more options for patients with earlier-stage disease, and growing ...

Now, Musunuru and colleagues are preparing a master clinical protocol to study a CRISPR therapy that's mostly the same as the one they used to treat baby KJ, except they plan to swap out the gene ...

The Recommended Uniform Screening Panel now includes DMD and MLD, which has implications for firms developing treatments for ...

While autologous therapies are mainstream in blood cancers, experts warn against overhyping allogeneic and in vivo approaches ...

The EGFR inhibitor's subcutaneous version heats up competition with AstraZeneca's Tagrisso in the front-line EGFR-mutated NSCLC space.

The company said the combo could help overcome resistance to EGFR inhibitors in patients whose tumors harbor the mutation.